Phase II study of90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma
- 20 November 2014
- journal article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 56 (6), 1750-1755
- https://doi.org/10.3109/10428194.2014.975801
Abstract
The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with (90)yttrium ((90)Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81% with advanced-stage disease and 44% with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [CI]: 65.6-97.7%), including a complete response in eight (50%), complete response unconfirmed in one (6%) and partial response in five (31%) patients. With a median follow-up of 65.6 months (range 4.0-96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0-93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40% (90% CI: 19.9-59.5%) and 5-year OS was 71.8% (90% CI: 46.8-86.5%). Overall, (90)Y ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.Keywords
This publication has 31 references indexed in Scilit:
- Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphomaAnnals of Oncology, 2007
- Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomasAnnals of Hematology, 2007
- Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphomaLeukemia & Lymphoma, 2007
- Long-Term Results of Anti– Helicobacter pylori Therapy in Early-Stage Gastric High-Grade Transformed MALT LymphomaJNCI Journal of the National Cancer Institute, 2005
- Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)Annals of Oncology, 2003
- Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeBlood, 2003
- Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classificationInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissueBlood, 2003
- Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression.Journal of Clinical Oncology, 1995